New combo pill attack targets Hard-to-Treat breast cancer

NCT ID NCT06365788

Recruiting now Disease control Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests two oral drugs, bicalutamide and abemaciclib, in 53 women with a specific type of advanced breast cancer called androgen receptor-positive triple-negative breast cancer. The goal is to see if the combination can stop the cancer from growing for at least 16 weeks. Researchers will also monitor side effects closely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bicalutamide and abemaciclib (oral tablets)
What this could lead to: If successful, this could offer a new targeted treatment option for a hard-to-treat form of breast cancer that has limited therapies.
What could go wrong: This is an early-phase, single-arm study with only 53 participants, so results may not apply broadly. Side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Kennedy disease triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST NEOPLASMS

Contacts and locations

Locations

Antwerp University Hospital
NOT_YET_RECRUITING

Antwerp, Belgium
Ghent University Hospital
RECRUITING

Ghent, Belgium
Jessa Ziekenhuis
RECRUITING

Hasselt, Belgium
University Hospital Brussels
RECRUITING

Brussels, Belgium
University Hospitals Leuven
RECRUITING

Leuven, Belgium
ZAS Augustinus
RECRUITING

Antwerp, 2610, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.